How Gilead’s CEO Moved Aggressively to Test and Distribute Remdesivir

This post was originally published on this site

In January, when Daniel O’Day had been chief executive of Gilead Sciences for not quite a year, his researchers told him about an experimental medicine called remdesivir, which might prove useful against the latest coronavirus outbreak. “It wasn’t an …

Click here to read full article